These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23251855)

  • 21. How dosing of ziprasidone in a state hospital system differs from product labeling.
    Citrome L; Jaffe A; Levine J
    J Clin Psychiatry; 2009 Jul; 70(7):975-82. PubMed ID: 19653974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
    Grootens KP; van Veelen NM; Peuskens J; Sabbe BG; Thys E; Buitelaar JK; Verkes RJ; Kahn RS
    Schizophr Bull; 2011 Mar; 37(2):352-61. PubMed ID: 19542525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
    Citrome L; Yang R; Glue P; Karayal ON
    Schizophr Res; 2009 Jun; 111(1-3):39-45. PubMed ID: 19375893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
    Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial.
    Bogers JPAM; Schulte PFJ; Broekman TG; Moleman P; de Haan L
    Eur Neuropsychopharmacol; 2018 Sep; 28(9):1024-1034. PubMed ID: 30025751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment.
    Stip E; Cherbal A; Luck D; Zhornitsky S; Bentaleb LA; Lungu O
    Psychopharmacology (Berl); 2017 Apr; 234(7):1045-1058. PubMed ID: 28210783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
    Zhang Y; Dai G
    Hum Psychopharmacol; 2012 Nov; 27(6):605-14. PubMed ID: 24446539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
    Hirsch SR; Kissling W; Bäuml J; Power A; O'Connor R
    J Clin Psychiatry; 2002 Jun; 63(6):516-23. PubMed ID: 12088164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
    Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
    CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder.
    Citrome L; Reist C; Palmer L; Montejano LB; Lenhart G; Cuffel B; Harnett J; Sanders KN
    Schizophr Res; 2009 Dec; 115(2-3):115-20. PubMed ID: 19864113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ziprasidone for schizophrenia and severe mental illness.
    Bagnall A; Lewis RA; Leitner ML; Kleijnen J
    Cochrane Database Syst Rev; 2000; (2):CD001945. PubMed ID: 10796670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration.
    Emul M; Dalkiran M; Coskun O; Yavuz R; Tosun M; Duran A; Ugur M; Keles I
    Pharmacol Res; 2009 Nov; 60(5):369-72. PubMed ID: 19647079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial.
    Cañas F; Pérez-Solá V; Díaz S; Rejas J;
    Clin Drug Investig; 2007; 27(9):633-45. PubMed ID: 17705572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
    Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
    J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
    Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M
    Neuropsychopharmacology; 1999 May; 20(5):491-505. PubMed ID: 10192829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review.
    Matza LS; Baker TM; Revicki DA
    CNS Drugs; 2005; 19(6):499-515. PubMed ID: 15963000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.
    Addington DE; Labelle A; Kulkarni J; Johnson G; Loebel A; Mandel FS
    Can J Psychiatry; 2009 Jan; 54(1):46-54. PubMed ID: 19175979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.